2,736
edits
mNo edit summary |
|||
Line 77: | Line 77: | ||
There are a few medicines and category of people which exclude patients from taking psychedelics: | There are a few medicines and category of people which exclude patients from taking psychedelics: | ||
* There is a theoretical interaction between [[SSRI and psychedelics|SSRIs and psychedelic]]<nowiki/>s. | * There is a theoretical interaction between [[SSRI and psychedelics|'''SSRIs''' and psychedelic]]<nowiki/>s. | ||
* There is some evidence to suggest olanzapine (an atypical antipsychotic) can ''terminate'' a trip<ref>'''Olanzapine as the ideal “trip terminator”?''' Giuseppe Valeriani, Ornella Corazza, Francesco Saverio Bersani. First published: 28 July 2015 <nowiki>https://doi.org/10.1002/hup.2431</nowiki>. Accessed via: <nowiki>https://onlinelibrary.wiley.com/doi/10.1002/hup.2431</nowiki></ref>. | * There is some evidence to suggest '''olanzapine''' (an atypical antipsychotic) can ''terminate'' a trip<ref>'''Olanzapine as the ideal “trip terminator”?''' Giuseppe Valeriani, Ornella Corazza, Francesco Saverio Bersani. First published: 28 July 2015 <nowiki>https://doi.org/10.1002/hup.2431</nowiki>. Accessed via: <nowiki>https://onlinelibrary.wiley.com/doi/10.1002/hup.2431</nowiki></ref>. | ||
* '''Kentanserin''' a research chemical and antagonist of 5-HT2A binds to the main psychedelic receptor but does not activate it. A recent study showed that giving participants kentanserin 1 hour after giving them LSD reduced the duration of LSD's subjective effects from around 8.5 hours to 3.5 hours<ref>'''Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects'''. Anna M Becker, Aaron Klaiber, Friederike Holze, Ioanna Istampoulouoglou, Urs Duthaler, Nimmy Varghese, Anne Eckert, Matthias E Liechti. ''International Journal of Neuropsychopharmacology'', 2022;, pyac075, <nowiki>https://doi.org/10.1093/ijnp/pyac075</nowiki></ref>. In theory, kentanserin might have use for reducing or terminating a psychedelic experience. | |||
* Presence or history of psychosis; | * Presence or history of psychosis; | ||
* Presence or history of mania or bipolar disorder; | * Presence or history of mania or bipolar disorder; |